Moderna not only recorded profits for the first quarter, but also raised the 2021 sales outlook for its covid-19 vaccine, as various countries ramp up their inoculation drive. Investors grew concerned, however, about the US proposing to temporarily lift patent protection for covid-19 vaccines.